Treatment of Hodgkin's disease: Current strategies of the German Hodgkin's Lymphoma Study Group

Annals of Oncology

Volumn 10, Issue SUPPL. 6, 1999, Pages

  Sieber, M ^a   Ruffer U ^a   Jostin, A ^a   Diehl, Volker ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Hodgkin's disease

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; DOSE RESPONSE; HODGKIN DISEASE; HUMAN; LAPAROTOMY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0342470528     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_6.S23     Document Type: Conference Paper

References (29)

1. Pusey WA. Cases of sarcoma and of Hodgkin's disease treated by exposures to X-rays: A preliminary report. JAMA 1902; 38: 166-9.
2. Senn N. Therapeutical value of röntgen ray in treatment of pseudoleukemia. New York Med J 1903; 77: 665-8.
3. Mauch P, Tarbell N, Weinstein H et al. Stage IA and IIA supradiaphragmatic Hodgkin's disease: Prognostic factors in surgically staged patients treated with mantle and para-aortic irradiation. J Clin Oncol 1988; 6: 1576-83.
4. DeVita VT Jr., Simon RM, Hubbard et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute Ann Intern Med 1980; 92: 587-95.
5. Bonadonna G, Zucali R, Monfardini et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazol carboximide versus MOPP. Cancer 1975; 36: 252-60.
6. Tubiana M, Henry-Amar M, Carde P et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood 1989; 73: 47-56.
7. Carde P, Hagenbeek A, Hayat M et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: The H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993; 11: 2258-72.
8. Henry-Amar M, Hayat M, Meerwaldt JH et al: Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols. Int J Radiation Oncology Biol Phys 1990; 19: 1155-7.
9. Hancock S, Tucker M, Hoppe R. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993; 270: 1949-55.
10. Van Leeuwen F, Klokman W, Hagenbeek A et al: Second cancer risk following Hodgkin's disease: A 20-year follow-up study. J Clin Oncol 1994; 12: 312-25.
11. Horning SJ, Hoppe RT, Hancock SL et al. Vinblastine, bleomycin, and methotrexate: An effective adjuvant in favorable Hodgkin's disease. J Clin Oncol 1988; 6: 1822-31.
12. Bates NP, Williams MV, Bessel EM et al. Efficacy and toxicity of vinblastine, bleomycin, and methotrexate with involved-field radiotherapy in clinical stage IA and IIA Hodgkin's disease: A British National Lymphoma Investigation pilot study. J Clin Oncol 1994; 12: 288-96.
13. Carde P, Noordijk EM, Hagenbeek A et al. Superiority of EBVP chemotherapy in combination with involved field irradiation (EBVP/ IF) over subtotal nodal irradiation (STNI) in favorable clinical stage (CS) I-II Hodgkin's disease: The EORTC-GPMC H7F randomized trial. Proc Am Soc Clin Oncol 1997; 16: 13.
14. Radford JA, Cowan RA, Ryder WDJ et al. Four weeks of neo-adjuvant chemotherapy significantly reduces the progression rate in patients treated with limited field radiotherapy for clinical stage (CS IA/IIA Hodgkin's disease. Results of a randomised pilot study. Ann Oncol 1996; 7: 66 (abstr).
15. Radford JA, Rohatiner AZS, Dunlop DJ et al. Preliminary results of a four-centre randomised trial paring weekly VAPEV-B (V) chemotherapy with the ChlVPP/EVA hybrid (H) regimen in previously untreated Hodgkin's disease (HD). Proc Am Soc Clin Oncol 1997; 16: 42 (abstr).
16. Noordijk EM, Carde P, Mandard AM et al. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. Ann Oncol 1994; 5: 107-12.
17. Loeffler M, Diehl V, Pfreundschuh M et al. Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease. J Clin Oncol 1997; 15: 2275-87.
18. Zittoun R, Audebert A, Hoerni B et al. Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease. J Clin Oncol 1985; 3: 207-14.
19. Santoro A, Bonfante V, Viviani S et al. Subtotal nodal (STNI) vs. involved field (IFRT) irradiation after 4 cycles of ABVD in early stage Hodgkin's disease. Proc Am Soc Clin Oncol 1996; 15: 1271 (abstr).
20. Canellos G P, Anderson JR, Propert et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478-84.
21. Klimo P, Connors, JM. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ ABV Hybrid program. Semin Hematol 1988; 25 (Suppl. 2): 34-40.
22. Connors JM, Klimo P, Adams et al. MOPP/ABV hybrid versus alternating MOPP/ABVD for advanced Hodgkin's disease. Proc. Am. Soc Clin Oncol 1992; 11: 317.
23. Viviani S, Bonadonna G, Santoro A et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results. J Clin Oncol 1996; 14: 1421-30.
24. Diehl V, Sieber M, Rüffer U et al. BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease. Ann Oncol 1997; 8: 143-8.
25. Diehl V, Tesch H, Lathan B et al. BEACOPP, a new intensified hybrid regimen, is at least equally effective compared with COPP/ABVD in patients with advanced stage Hodgkin's disease. Proc Am Soc Clin Oncol 1997; 16: 5, b (abstr).
26. Löffler M, Brosteanu O, Hasenclever D et al. Meta-Analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. J Clin Oncol 1998; 16 (3): 818-29.
27. Proctor, SJ, Taylor, PRA. Classical staging of Hodgkin's disease is inappropriate for selecting patients for clinical trials of intensive therapy: The case for the objective use of prognostic factor informations in addition to classical staging. Leukemia 1993; 7: 1911.
28. Strauss DJ, Gaynor JJ, Myers J et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 1990; 8: 1173-86.
29. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. New Engl J Med 1998; 339: 1506-14.